<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777723</url>
  </required_header>
  <id_info>
    <org_study_id>164DES16001</org_study_id>
    <nct_id>NCT02777723</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of CKD-350</brief_title>
  <official_title>Active Controlled, Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-350 Eye Drops in Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of CKD-350 in patients with
      dry eye syndrome
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active controlled, randomized, double-blind, multi-center, phase 3 trial to evaluate the
      efficacy and safety of CKD-350 eye drops in patients with dry eye syndrome
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Corneal Staining by Oxford scale from Baseline and at Week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Corneal Staining by Oxford scale from Baseline and at Week 2</measure>
    <time_frame>Baseline, week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Tear Break-up Time from Baseline and at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Schirmer I Test from Baseline and at Week 2, 4</measure>
    <time_frame>Baseline, Week 2, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Ocular Surface Disease Index from Baseline and at week 2, 4</measure>
    <time_frame>Baseline, week 2, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>CKD-350</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xenobella</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isotonic 0.3% Sodium Hyaluronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenobella</intervention_name>
    <description>Hypotonic 0.3% Sodium Hyaluronate</description>
    <arm_group_label>CKD-350</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic 0.3% Sodium Hyaluronate</intervention_name>
    <description>Isotonic 0.3% Sodium Hyaluronate</description>
    <arm_group_label>Sodium Hyaluronate</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than the age of 19 years old

          2. Subjects with dry eye symptoms for at least 3 month prior to screening

          3. Subjects who have following values 1) ≥ 2 point of corneal staining score 2) ≤ 10
             seconds of Tear Break-up Time 3) ≤10mm/5min of Schirmer I Test

          4. Subjects who have a visual acuity equal to or better than 0.2 in both eyes

          5. Subjects who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Subjects who have clinically significant ocular surface diseases, abnormal corneal
             susceptibility and abnormal epiphora

          2. Subjects who have medical history following 1) Abnormal eyelids function including
             abnormality of eyelid or eyelash 2) Ophthalmology operation within 1 year 3) Active
             ocular infection at present or treatment of allergic eye diseases 4) Herpetic
             keratopathy, conjunctiva scar from cicatricial keratoconjunctivitis(alkali injuries,
             stevens-johnson syndrome, ocular cicatricial pemphigoid), pterygium, congenital
             lacrimal gland absence, neural keratitis, keratoconus

          3. Subjects who have received occlusion therapy with lacrimal or punctal plugs within 3
             months or have a surgery plan in clinical trial

          4. Subjects who wore contact lenses within 3 months or need to wear contact lenses during
             the study

          5. Subjects who take steroidal or immunosuppressive drug within 1 month

          6. Over 22mmHg IOP(Intraocular Pressure)

          7. Subjects who have malignant tumor within 5 years

          8. Subjects with known hypersensitivity to investigational product

          9. Women who are nursing, pregnant or planning pregnancy during the study

         10. Subjects who have received any other investigational product within 1 month prior to
             the first dosing

         11. Impossible subjects who participate in clinical trial by investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HyoMyung Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Chungcheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SiHwan Choi, MD</last_name>
      <phone>82-10-5427-7609</phone>
      <email>shchoi@cnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>SeongNam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoonYoung Hyon, MD</last_name>
      <phone>82-10-2735-8123</phone>
      <email>jyhyon@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HongKyun Kim, MD</last_name>
      <phone>82-10-4509-4886</phone>
      <email>okeye@knu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JongSu Lee, MD</last_name>
      <phone>82-10-9021-2498</phone>
      <email>jongsool@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>InChun You, MD</last_name>
      <phone>82-10-3292-1824</phone>
      <email>you2ic@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyungChul Yoon, MD</last_name>
      <phone>82-10-9220-0234</phone>
      <email>kcyoon@chonnam.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HungWon Tchah, MD</last_name>
      <phone>82-10-8177-8000</phone>
      <email>hwtchah@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HyungKeun Lee, MD</last_name>
      <phone>82-10-6202-7164</phone>
      <email>shadik@yumc.yonsei.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University ANAM Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyoMyoung Kim, MD</last_name>
      <phone>82-10-5415-5776</phone>
      <email>hyomkim@daum.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University GURO Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JongSeok Song, MD</last_name>
      <phone>82-10-9494-1606</phone>
      <email>song1606@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TaeYoung Chung, MD</last_name>
      <phone>82-10-9933-3563</phone>
      <email>tychung@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MeeKum Kim, MD</last_name>
      <phone>82-10-6277-0798</phone>
      <email>kmk9@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul ST. MARY'S Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SoHyang Chung, MD</last_name>
      <phone>82-10-6313-6202</phone>
      <email>chungsh@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TaeIm Kim, MD</last_name>
      <phone>82-10-6309-9639</phone>
      <email>tikim@yumc.yonsei.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>Sodium Hyaluronate</keyword>
  <keyword>CKD-350</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

